- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 08.10. | Reviva Pharmaceuticals: Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit | 1 | GlobeNewswire (USA) | ||
| 07.10. | Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst | 31 | Benzinga.com | ||
| 02.10. | Reviva Pharmaceuticals: Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference | 3 | GlobeNewswire (USA) | ||
| 26.09. | Reviva Pharmaceuticals to Participate in the Lytham Partners Fall 2024 Investor Conference | 1 | GlobeNewswire (USA) | ||
| 23.09. | EF Hutton setzt Kaufempfehlung für Reviva Pharmaceuticals-Aktien | - | Investing.com Deutsch | ||
| 23.09. | EF Hutton sets Buy rating on Reviva Pharmaceuticals shares | 1 | Investing.com | ||
| 17.09. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 09.09. | Reviva Pharmaceuticals: Reviva Announces New Vocal Biomarker Data from Phase 3 RECOVER Trial of Brilaroxazine in Schizophrenia | 236 | GlobeNewswire (Europe) | - Statistically significant vocal biomarker speech latency data reinforce the strong efficacy of brilaroxazine for negative symptoms and other key symptom domains of schizophrenia - - Additional vocal... ► Artikel lesen | |
| 21.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 21.08. | Reviva Pharmaceuticals stock falls after it prices $5M offering | 1 | Seeking Alpha | ||
| 21.08. | Reviva Pharmaceuticals Announces Pricing of $5.0 Million Underwritten Offering Priced At-the-Market Under Nasdaq Rules | 2 | GlobeNewswire (USA) | ||
| 15.08. | Reviva Pharmaceuticals GAAP EPS of -$0.26 | 3 | Seeking Alpha | ||
| 14.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 14.08. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 09.07. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 09.07. | Reviva Pharmaceuticals: Reviva Announces Grant of European Patent Covering Use of Brilaroxazine for the Treatment of Pulmonary Hypertension | 192 | GlobeNewswire (Europe) | - Patent covers brilaroxazine use for treating pulmonary hypertension (PH), pulmonary arterial hypertension (PAH) in any patients including treating PH in patients with chronic obstructive pulmonary... ► Artikel lesen | |
| 29.05. | Reviva Pharmaceuticals: Reviva Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules | 4 | GlobeNewswire (USA) | ||
| 29.05. | REVIVA PHARMACEUTICALS HOLDINGS, INC. - 8-K, Current Report | 3 | SEC Filings | ||
| 28.05. | Reviva Pharmaceuticals looks to raise $3M through direct offering; shares fall | 2 | Seeking Alpha | ||
| 21.05. | Reviva Pharmaceuticals: Reviva to Participate in the BIO International Convention | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
31 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VIATRIS | 10,710 | -0,09 % | Earnings Preview: What To Expect From Viatris' Report | ||
| GREEN THUMB INDUSTRIES | 9,450 | -0,21 % | Should You Buy Canopy Growth Stock or Green Thumb Stock Today? | ||
| ASTRIA THERAPEUTICS | 10,200 | -2,86 % | Astria Therapeutics, Inc.: Astria Therapeutics to Present at Upcoming Global Angioedema Forum | Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced that leading HAE experts... ► Artikel lesen | |
| NEWRON PHARMACEUTICALS | 8,870 | +3,50 % | Newron SpA Aktie: Stabile Performance trotz Herausforderungen | ||
| CASSAVA SCIENCES | 23,980 | -0,50 % | Cassava Sciences, Inc.: Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024 | ||
| ORAMED PHARMACEUTICALS | 2,143 | -0,14 % | ORAMED PHARMACEUTICALS INC. - 8-K, Current Report | ||
| ROCKET LAB USA | 10,440 | -0,76 % | Could Rocket Lab Be a Millionaire-Maker Stock in the Trillion-Dollar Space Industry? | ||
| AURINIA PHARMACEUTICALS | 6,584 | +0,89 % | On behalf of Lucien Selce: Aurinia Pharmaceuticals Shareholder Calls for CEO Peter Greenleaf, Dr. Brinda Balakrishnan, and Dr. Robert Foster to Resign from the Board | Highlights Damning Annual General Meeting Results, Which Show That Four of the Company's Nine Directors Failed to Receive a Majority of the Votes Calls on the Company to Appoint Two Shareholder... ► Artikel lesen | |
| LIPOCINE | 6,130 | +12,27 % | Lipocine Partners with SPC Korea for TLANDO in South Korea | ||
| BOIRON | 32,450 | +1,25 % | BOIRON: EVOLUTION OF GOVERNANCE | July 3rd, 2024
The Board of Directors of Laboratoires BOIRON, meeting today under the chairmanship of Thierry BOIRON, has enacted an evolution of the Group's governance.
In this context, Thierry... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 5,550 | +2,78 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Presentation of Promising Phase I Data Evaluating Concurrent Paxalisib and Radiation Therapy in Patients with Solid Tumor Brain Metastases or Leptomeningeal Metastases Harboring ... | Treatment with 45mg paxalisib and radiotherapy demonstrated 67% partial response (PR)
Over two-thirds of the patients at maximum tolerated dose (MTD) achieved intracranial response which compares favorably... ► Artikel lesen | |
| ALLERGY THERAPEUTICS | 0,059 | -3,31 % | Allergy Therapeutics - Commencement of Phase III Paediatric Trial | ||
| HARROW | 45,500 | +1,97 % | Harrow Unusual Options Activity For October 28 | ||
| MEDICINOVA | 1,600 | 0,00 % | MediciNova, Inc.: MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium) | LA JOLLA, Calif., Oct. 23, 2024 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange... ► Artikel lesen | |
| ESSA PHARMA | 1,520 | -69,66 % | Pre-market Movers: ESSA Pharma, Theriva Biologics, VS MEDIA, Lexicon Pharmaceuticals, Athira Pharma | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 08.00 A.M. ET).In the Green Theriva Biologics, Inc. (TOVX) is up over 47% at $2.15.
VS... ► Artikel lesen |
Das Unternehmen REVIVA PHARMACEUTICALS HOLDINGS INC kann der Branche Pharma zugeordnet werden. Der aktuelle Kurs liegt bei 0,995 Euro und damit -11,16 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu REVIVA PHARMACEUTICALS HOLDINGS INC finden Sie auf Wallstreet Online.
